Related Experiment Video
Updated: Aug 17, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Fibrinolytic and antithrombotic regimens in recently completed, ongoing and planned clinical trials in myocardial
Abstract:
Myocardial infarction carries significant short-term and long-term risks of morbidity and mortality. Traditional treatment for acute myocardial infarction has significantly improved the outcomes of patients suffering from this condition. Recent clinical trials have focused on the use of novel fibrinolytics, glycoprotein IIb/IIIa receptor antagonists, low-molecular-weight heparin, direct thrombin inhibitors and myocardial protection, in an attempt to improve the prognosis of these patients. This clinical trials report reviews the rationale and design of recently completed, ongoing and planned major Phase II and III clinical trials on fibrinolytic and antithrombotic regimens for the treatment of myocardial infarction.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Myocarditis III: Medical Management
Clot Retraction and Fibrinolysis